Trials / Completed
CompletedNCT05445895
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
A Prospective, Randomized, Active-controlled, Double-blind, Parallel, Multi-center, Phase IV, Exploratory Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 483 (actual)
- Sponsor
- SK Chemicals Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A study to Evaluate the Efficacy and Safety of Renexin CR in patients with Acute Non-cardioembolic Ischemic Stroke
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Renexin CR 200/160mg | Renexin CR 200/160mg will be added to Aspirin 100mg |
| DRUG | Plavix 75mg | Plavix 75mg will be added to Aspirin 100mg |
Timeline
- Start date
- 2022-12-16
- Primary completion
- 2025-10-02
- Completion
- 2025-11-07
- First posted
- 2022-07-06
- Last updated
- 2025-11-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05445895. Inclusion in this directory is not an endorsement.